Susquehanna International Group
BTAI icon

Susquehanna International Group’s BioXcel Therapeutics BTAI Stock Holding History

Susquehanna International Group’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.3K Buy
+17,200
New +$20.1K ﹤0.01% 13005
2025
Q1 		– Sell
-2,158
Closed -$12.9K – 12531
2024
Q4 		$12.9K Buy
2,158
+20
+0.9% +$167 ﹤0.01% 11965
2024
Q3 		$20.9K Sell
2,138
-8,694
-80% -$117K ﹤0.01% 11619
2024
Q2 		$222K Buy
10,832
+5,195
+92% +$174K ﹤0.01% 10120
2024
Q1 		$254K Buy
+5,637
New +$269K ﹤0.01% 10085
2023
Q4 		– Sell
-1,216
Closed -$67.6K – 12387
2023
Q3 		$49.2K Sell
1,216
-14,471
-92% -$1.46M ﹤0.01% 11313
2023
Q2 		$1.67M Buy
15,687
+11,813
+305% +$3.93M ﹤0.01% 5526
2023
Q1 		$1.16M Buy
3,874
+2,610
+206% +$1.11M ﹤0.01% 6432
2022
Q4 		$435K Sell
1,264
-1,995
-61% -$482K ﹤0.01% 8231
2022
Q3 		$616K Sell
3,259
-1,722
-35% -$400K ﹤0.01% 7915
2022
Q2 		$1.05M Sell
4,981
-2,794
-36% -$588K ﹤0.01% 6404
2022
Q1 		$2.6M Sell
7,775
-3,339
-30% -$968K ﹤0.01% 4891
2021
Q4 		$3.62M Sell
11,114
-3,838
-26% -$1.65M ﹤0.01% 4324
2021
Q3 		$7.26M Buy
14,952
+1,540
+11% +$677K ﹤0.01% 3345
2021
Q2 		$6.24M Buy
13,412
+1,519
+13% +$828K ﹤0.01% 3626
2021
Q1 		$8.21M Buy
11,893
+2,360
+25% +$1.9M ﹤0.01% 3099
2020
Q4 		$7.05M Sell
9,533
-4,870
-34% -$3.79M ﹤0.01% 2929
2020
Q3 		$9.99M Buy
14,403
+14,160
+5,827% +$10.6M ﹤0.01% 2176
2020
Q2 		$206K Buy
+243
New +$158K ﹤0.01% 8988

Other funds holding BTAI

Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OFA
Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Susquehanna International Group's BTAI Position: Q2 2026 in Review

Susquehanna International Group opened a new position in BioXcel Therapeutics (BTAI) in Q2 2026: 17,200 shares worth $24.3K. The stake represents ﹤0.01% of the portfolio and ranks #13005 among its holdings. This is a return to the name: Susquehanna International Group previously reported a position in BTAI as recently as Q4 2024.

Susquehanna International Group first reported a position in BTAI in Q2 2020 and has held it in 19 quarters since. The position peaked at $9.99M in Q3 2020. 47 funds tracked by Wall St. Rank hold BTAI as of Q2 2026.

  • Susquehanna International Group held 17,200 shares of BioXcel Therapeutics worth $24.3K as of Q2 2026.
  • BioXcel Therapeutics was a new Susquehanna International Group position in Q2 2026.
  • BioXcel Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q2 2026, its #13005 holding.
  • Susquehanna International Group first reported a position in BioXcel Therapeutics in Q2 2020 and has held it in 19 quarters since.
  • Susquehanna International Group's BioXcel Therapeutics position peaked at $9.99M in Q3 2020.
  • 47 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.